Atorvastatin Inhibits Breast Cancer Cells by Downregulating PTEN/AKT Pathway via Promoting Ras Homolog Family Member B (RhoB)

Figure 1

Atorvastatin inhibits proliferation, migration, and EMT of breast cancer cells, while promoting cell apoptosis. MDA-MB-231 cells were treated with 4μM ATO and MCF-7 cells were treated with 2 μM ATO in (b), (c), (d), (e), and (f). (a) ATO inhibits the proliferation of breast cancer cells determined by CCK-8 assay. (b) ATO suppresses the proliferation of breast cancer cells determined by the clone formation assay. (c) After being treated with ATO for 48 h, the corresponding proteins of EMT were evaluated in breast cancer cells by Western blotting. (d) Wound healing assay reveals that ATO reduces the ability of migration of breast cancer cells. (e) ATO suppresses the invasion of breast cancer cells which were revealed by transwell assay. (f) ATO induces early apoptosis and late apoptosis of breast cancer cells which was detected by annexin V-FITC and PI staining. Data were presented as mean ± SD from three independent measurements. p < 0.05.

(a)

(b)

(c)

(d)

(e)

(f)